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Butyric acid-producing anaerobic bacteria as a novel probiotic
treatment approach for inflammatory bowel disease
Inflammatory bowel disease (IBD), of
which Crohn’s disease (CD) and ulcerative
colitis (UC) are the most common
manifestations, is characterized by chronic
inflammation of the lining of the
gastrointestinal tract, which causes severe
watery and bloody diarrhoea, and
abdominal pain. IBD is often debilitating
and is characterized by onset at a young
age and extra-intestinal manifestations.
Whereas CD can affect any part of the
gastrointestinal tract, UC is usually
confined to the colon and rectum. IBD is
an emerging disease and the incidence
amounts to 20/100 000 in Europe and
North America. There is a link with the
social and economic development of the
countries: the increase in IBD was first
seen in northern Europe and North
America, followed by the rest of Europe,
Japan, South America and certain parts of
Asia (Cohen, 2000; Ouyang et al., 2005).
Although the exact aetiopathogenesis of
IBD are not clear, it is widely accepted that
the disease derives from an inappropriate
immune response in genetically susceptible
individuals as the result of a complex
interaction between environmental factors,
the microbiota and the intestinal immune
system (Danese & Fiocchi, 2006).
In IBD, the response to conventional drug
therapy is suboptimal. This therapy is
associated with a number of disadvantages,
including a considerable burden of side
effects, and surgery is still required in a
subgroup of patients. Because IBD
represents a distortion of the relationship
between the gut microbiota and the host
response, probiotics and prebiotics have
been proposed as possible therapeutic
products. The probiotics that are being
tested for treatment of IBD are mainly
lactic acid bacteria, i.e. lactobacilli and
bifidobacteria. Although a decrease in the
number of lactic acid bacteria has been
shown in IBD, administration of lactic acid
bacteria has yielded inconsistent results
with respect to the treatment of IBD
(Gueimonde et al., 2007; Hedin et al.,
2007). The only well-documented
indication for the use of probiotics in IBD
is in the treatment of pouchitis,
particularly using a mixed lactobacilli–
bifidobacteria product (Mimura et al.,
2004). Many trials using probiotics either
as maintenance therapy in UC, to treat
active UC, to maintain remission in CD, or
to treat active CD, have yielded mixed
results, concluding that their use cannot be
recommended based on the available
evidence (Hedin et al., 2007).
Butyric acid, produced within the intestinal
lumen by bacterial fermentation of dietary
carbohydrates, exerts a wide variety of
effects on intestinal function (Hamer et al.,
2008). First of all, butyric acid is the
preferred source of energy for colonocytes.
It affects cellular proliferation,
differentiation and apoptosis. Moreover,
butyric acid has well documented anti-
inflammatory effects. Inhibition of histone
deacetylase activity, resulting in
hyperacetylation of histones, and as a
consequence suppression of nuclear factor-
kappa B activation, is a likely explanation.
Secondly, it has been proposed that butyric
acid reinforces the colonic defence barrier
by increasing production of mucins and
antimicrobial peptides. Thirdly, it has been
shown that butyric acid decreases intestinal
epithelial permeability by increasing the
expression of tight junction proteins. Anti-
inflammatory activities, combined with a
strengthening of the mucosal barrier
integrity, are ideal properties for therapeutic
compounds against IBD-like syndromes.
Indeed it has been shown that butyrate
enemas can yield positive results in the
treatment of active UC (Breuer et al., 1997).
Butyric acid thus has a potential therapeutic
value against IBD, but the actual delivery
into the gut is still problematic. Several
mechanisms are possible.
(a) Fermentation of dietary fibre leads
to butyrate production. An
increase in butyrate production
may result from a direct
stimulation of butyrate producers
or indirect effects such as
metabolic cross-feeding of
fermentation products from other
bacterial groups (Flint et al., 2007).
(b) The use of butyric acid-coated
tablets is a possible delivery
method, but the tablets may not
always release their content at the
intended location because of inter-
individual differences in gut lumen
pH and transit time. Moreover the
taste is very unpleasant. Alternative
approaches are the consumption of
butyrylated starch and the use of
butyryl-L-carnitine as a potential
prodrug (Srinivas et al., 2007;
Bajka et al., 2008).
(c) Rectal butyric acid enemas hold
promise but the use of enemas is
often hampered by a low
compliance rate, and a short and
discontinuous exposure of the
colon mucosa to the butyrate
(Breuer et al., 1997).
(d) A final possibility is the
administration of colonizing
butyric acid-producing bacteria,
enabling in situ production of
butyric acid.
Several studies have shown that,
numerically, the majority of butyrate-
producing bacteria found in human faeces
are highly oxygen-sensitive anaerobes
belonging to the clostridial clusters IV and
XIVa (Louis & Flint, 2009). Decreases in
members of the butyrate-producing
clostridial clusters IV and XIVa have been
reproducibly reported in the gut of IBD
patients (Sokol et al., 2008; Takaishi et al.,
2008). These species are thus probiotic
candidates for the treatment of IBD.
Recently, considerable progress has been
made in the isolation of these strictly
anaerobic butyric acid-producing bacteria
from the human gut. It has been shown
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that lactic acid, produced in vitro by lactic
acid bacteria, is used by some strictly
anaerobic butyrate-producing bacteria of
clostridial cluster XIVa for the production
of high concentrations of butyric acid
(Louis & Flint, 2009). This mechanism is
called cross-feeding and could explain why
administration of lactic acid bacteria to IBD
patients can in certain cases be an
advantage, i.e. through stimulation of
butyric acid production. However, other
possible mechanisms of action, including
immunoregulatory effects, also have been
suggested (Geier et al., 2007). An ideal
probiotic would thus be a colonizing
bacterium that combines systemic anti-
inflammatory and immunoregulatory
effects with delivery of high butyrate levels
at the site of action and that can be ingested
in a stable form, such as spores. One
potential problem is that bowel conditions
in IBD patients may not be optimal to
support growth of these bacterial species.
However, butyrate producers present in the
colon are phylogenetically diverse and it has
not been investigated in detail yet which
species are decreased in IBD. Therefore, it is
likely that strains can be identified that are
good colonizers. Furthermore, a synbiotic
approach, using a prebiotic in combination
with a butyrate producer, may help to re-
establish such bacteria in the individual in
the diseased state. First attempts have been
made in animal models of IBD to apply
butyrate-producing bacteria (Sokol et al.,
2008; Eeckhaut et al., 2009). Strains of
clostridium cluster IV and XIVa were found
to be highly successful in decreasing
inflammation and necrosis in rodent IBD
models. Indeed, Faecalibacterium
prausnitzii, a species belonging to cluster IV,
has been shown to be much less prevalent in
the gut microbiota of IBD patients. This
species showed great promise in
counterbalancing dysbiosis in a mouse IBD
model (Sokol et al., 2008, 2009).
Interestingly, components of the culture
supernatant of this bacterium had the
capacity to decrease production of the
inflammatory cytokines interleukin 12 and
gamma interferon, and to increase
production of the anti-inflammatory
cytokine interleukin 10, in peripheral blood
mononuclear cells in a way independent of
butyrate (Sokol et al., 2008). Oral and
intraperitoneal administration of the
culture supernatant in a mouse IBD model
reduced colitis and mortality, respectively
(Sokol et al., 2008). This clearly suggests
that F. prausnitzii secretes certain molecules
that have the potential to be used as
therapeutics. In fact it has not been resolved
whether butyrate is the key molecule in the
anti-colitis effects of F. prausnitzii or
whether these depend on a combination of
secreted compounds yet-to-be identified
that might act independently or together
with butyrate. Notably, however, F.
prausnitzii administration led to a shift in
the microbiota composition that could also
have complex effects on colitis (Sokol et al.,
2008). It has been shown that the inflamed
intestinal mucosa of IBD patients has a
defective butyrate metabolism, leading to
reduced efficiency of butyrate, again
suggesting that other compounds in
addition to butyrate may be involved in the
beneficial effects of the butyrate-producing
microbiota (Thibault et al., 2010).
Nevertheless, it is clear that the pool of
butyrate-producing bacteria from clostridial
cluster IV and XIVa harbours very
promising preventive and therapeutic
probiotic strains. In a comparative study
using four strains, it was shown that a
particular strain from clostridium cluster IV,
Butyricicoccus pullicaecorum, was superior in
decreasing lesions in a rat IBD model
compared to F. prausnitzii (Eeckhaut et al.,
2009). It is therefore suggested that research
efforts should be increased to test the
therapeutic value of these next generation
probiotic strains, and to identify further
strains that are able to colonize the gut of
IBD patients without being outcompeted.
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